Dual-Agent Molecular Targeting of the ErbB2 Receptor: Killing One Bird With Two Stones
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- July 10, 2008
has subject area
- 1103 Clinical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Antibodies, Monoclonal (MeSH)
- Antibodies, Monoclonal, Humanized (MeSH)
- Antineoplastic Combined Chemotherapy Protocols (MeSH)
- Breast Neoplasms (MeSH)
- Dose-Response Relationship, Drug (MeSH)
- Drug Administration Schedule (MeSH)
- Drug Delivery Systems (MeSH)
- Female (MeSH)
- Humans (MeSH)
- Lapatinib (MeSH)
- Oncology & Carcinogenesis (Science Metrix)
- Prognosis (MeSH)
- Quinazolines (MeSH)
- Receptor, ErbB-2 (MeSH)
- Survival Analysis (MeSH)
- Trastuzumab (MeSH)
- Treatment Outcome (MeSH)
published in
- Journal of Clinical Oncology Journal